OP Asset Management Ltd Takes $404,000 Position in Charles River Laboratories International, Inc. $CRL

OP Asset Management Ltd acquired a new position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) during the 1st quarter, according to its most recent filing with the SEC. The institutional investor acquired 2,340 shares of the medical research company’s stock, valued at approximately $404,000.

Other hedge funds have also modified their holdings of the company. Invesco Ltd. increased its position in Charles River Laboratories International by 115.8% during the fourth quarter. Invesco Ltd. now owns 2,696,150 shares of the medical research company’s stock worth $537,828,000 after purchasing an additional 1,446,972 shares during the last quarter. Massachusetts Financial Services Co. MA acquired a new position in shares of Charles River Laboratories International in the 4th quarter valued at $176,478,000. Victory Capital Management Inc. grew its stake in shares of Charles River Laboratories International by 9,938.8% during the 4th quarter. Victory Capital Management Inc. now owns 691,474 shares of the medical research company’s stock valued at $137,935,000 after buying an additional 684,586 shares during the period. Ameriprise Financial Inc. increased its holdings in shares of Charles River Laboratories International by 1,491.1% during the 3rd quarter. Ameriprise Financial Inc. now owns 613,604 shares of the medical research company’s stock worth $96,005,000 after buying an additional 575,039 shares during the last quarter. Finally, National Bank of Canada FI increased its holdings in shares of Charles River Laboratories International by 117.7% during the 3rd quarter. National Bank of Canada FI now owns 946,769 shares of the medical research company’s stock worth $148,131,000 after buying an additional 511,901 shares during the last quarter. 98.91% of the stock is owned by institutional investors and hedge funds.

Charles River Laboratories International Trading Up 0.5%

NYSE:CRL opened at $226.61 on Wednesday. The business’s 50-day moving average is $178.79 and its two-hundred day moving average is $183.83. The firm has a market capitalization of $10.92 billion, a PE ratio of -60.27, a price-to-earnings-growth ratio of 2.58 and a beta of 1.46. Charles River Laboratories International, Inc. has a 12 month low of $144.26 and a 12 month high of $228.88. The company has a debt-to-equity ratio of 0.90, a current ratio of 1.36 and a quick ratio of 1.03.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Thursday, May 7th. The medical research company reported $2.06 earnings per share for the quarter, topping the consensus estimate of $1.96 by $0.10. Charles River Laboratories International had a positive return on equity of 15.36% and a negative net margin of 4.59%.The company had revenue of $995.83 million during the quarter, compared to the consensus estimate of $977.46 million. During the same quarter in the prior year, the business earned $2.34 earnings per share. The company’s revenue was up 1.2% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. Research analysts predict that Charles River Laboratories International, Inc. will post 11.05 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently weighed in on CRL shares. Evercore reiterated an “outperform” rating and issued a $220.00 target price on shares of Charles River Laboratories International in a report on Friday, May 8th. JPMorgan Chase & Co. dropped their price target on Charles River Laboratories International from $165.00 to $160.00 and set a “neutral” rating for the company in a research note on Monday, April 13th. Weiss Ratings downgraded Charles River Laboratories International from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 16th. Barclays raised their price target on shares of Charles River Laboratories International from $210.00 to $220.00 and gave the company an “overweight” rating in a report on Friday, May 8th. Finally, CLSA raised shares of Charles River Laboratories International from a “hold” rating to an “outperform” rating and lifted their price target for the company from $167.00 to $219.00 in a research report on Friday, May 29th. Twelve analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Charles River Laboratories International presently has an average rating of “Moderate Buy” and a consensus target price of $211.00.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.